A Major Shortcoming in the Public Health Legacy of the Obama Administration
Contrary to the Obama Administration's commitment to cure cancer, the FDA approved many cancer drugs based on shorter-term studies of smaller numbers of patients, usually allowing companies to study outcomes measured by biomarkers rather than meaningful clinical outcomes such as survival or fewer days in the hospital.3 The FDA required postmarket studies to shore up that weaker scientific evidence, but only a small minority reported a significant clinical benefit.3 The problem of unproven treatments is not unique to cancer drugs; once a drug or medical device is on the market, it stays there for many years even when its safety and benefits are not confirmed.4,5 This contributes to skyrocketing health care and insurance costs, as patients pay for expensive new treatments that are ineffective or inferior to older, less expensive treatments. Unfortunately, his only words about FDA focused on the need for "new and innovative" treatments, rather than safe, effective, or affordable ones. Since he apparently isn't beholden to pharmaceutical and medtech company contributions, can he be persuaded to follow through on his populist promises by helping patients get what they really want-treatments that work and don't destroy their quality of life?.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:107 |
|---|---|
| Enthalten in: |
AJPH - 107(2017), 1, Seite 29-30 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zuckerman, Diana M [VerfasserIn] |
|---|
| Links: |
|---|
| RVK: |
|---|
| doi: |
10.2105/AJPH.2016.303559 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1988142903 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1988142903 | ||
| 003 | DE-627 | ||
| 005 | 20230517060930.0 | ||
| 007 | tu | ||
| 008 | 170207s2017 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.2105/AJPH.2016.303559 |2 doi | |
| 028 | 5 | 2 | |a PQ20170301 |
| 035 | |a (DE-627)OLC1988142903 | ||
| 035 | |a (DE-599)GBVOLC1988142903 | ||
| 035 | |a (PRQ)c697-6a51217cb7d15e7cc8ceca6cf2d1e1415f472cf522f82e7d417cff58cce1f34a0 | ||
| 035 | |a (KEY)0074575820170000107000100029majorshortcominginthepublichealthlegacyoftheobamaa | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DNB |
| 084 | |a XA 10000 |q AVZ |2 rvk | ||
| 084 | |a 44.10 |2 bkl | ||
| 100 | 1 | |a Zuckerman, Diana M |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A Major Shortcoming in the Public Health Legacy of the Obama Administration |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Contrary to the Obama Administration's commitment to cure cancer, the FDA approved many cancer drugs based on shorter-term studies of smaller numbers of patients, usually allowing companies to study outcomes measured by biomarkers rather than meaningful clinical outcomes such as survival or fewer days in the hospital.3 The FDA required postmarket studies to shore up that weaker scientific evidence, but only a small minority reported a significant clinical benefit.3 The problem of unproven treatments is not unique to cancer drugs; once a drug or medical device is on the market, it stays there for many years even when its safety and benefits are not confirmed.4,5 This contributes to skyrocketing health care and insurance costs, as patients pay for expensive new treatments that are ineffective or inferior to older, less expensive treatments. Unfortunately, his only words about FDA focused on the need for "new and innovative" treatments, rather than safe, effective, or affordable ones. Since he apparently isn't beholden to pharmaceutical and medtech company contributions, can he be persuaded to follow through on his populist promises by helping patients get what they really want-treatments that work and don't destroy their quality of life? | ||
| 650 | 4 | |a Populism | |
| 650 | 4 | |a Minority & ethnic groups | |
| 650 | 4 | |a Medicare | |
| 650 | 4 | |a Studies | |
| 650 | 4 | |a Narcotics | |
| 650 | 4 | |a Clinical trials | |
| 650 | 4 | |a Health disparities | |
| 650 | 4 | |a Cancer | |
| 650 | 4 | |a Public health | |
| 650 | 4 | |a Decision making | |
| 650 | 4 | |a Cancer therapies | |
| 650 | 4 | |a Medical equipment | |
| 650 | 4 | |a Sex crimes | |
| 650 | 4 | |a Political campaigns | |
| 650 | 4 | |a FDA approval | |
| 650 | 4 | |a Standards | |
| 650 | 4 | |a Medical technology | |
| 650 | 4 | |a Drugs | |
| 650 | 4 | |a Government agencies | |
| 773 | 0 | 8 | |i Enthalten in |t AJPH |d Washington, DC : APHA, 1911 |g 107(2017), 1, Seite 29-30 |w (DE-627)129295396 |w (DE-600)121100-6 |w (DE-576)014488671 |x 0090-0036 |7 nnns |
| 773 | 1 | 8 | |g volume:107 |g year:2017 |g number:1 |g pages:29-30 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.2105/AJPH.2016.303559 |3 Volltext |
| 856 | 4 | 2 | |u http://search.proquest.com/docview/1853308677 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_11 | ||
| 912 | |a GBV_ILN_4219 | ||
| 936 | r | v | |a XA 10000 |
| 936 | b | k | |a 44.10 |q AVZ |
| 951 | |a AR | ||
| 952 | |d 107 |j 2017 |e 1 |h 29-30 | ||